Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

MSKCC (Motzer) Score

The Memorial Sloan Kettering Cancer Center (MSKCC) or Motzer Score is a prognostic model used to risk-stratify patients with metastatic renal cell carcinoma (mRCC).

Evidence-based context for fast calculator use

Purpose:
MSKCC (Motzer) Score stratifies metastatic renal cell carcinoma into risk groups to guide first-line systemic therapy selection for mRCC patients.
Population:
patients undergoing localized or metastatic renal cell carcinoma prognostic assessment
Factors:
Karnofsky Performance Status< 80%?, Serum LDH > 1.5 x Upper Limit of Normal?, Hemoglobin < Lower Limit of Normal?, Corrected Serum Calcium > 10 mg/dL?, Time from diagnosis to systemic treatment < 1 year?
Reference:
Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20(1):289-296.
HomeMSKCC (Motzer) Score
Pin your most used calculators here by clicking the star in the dropdown.

MSKCC (Motzer) Score

Clinical Context & Background

The Memorial Sloan Kettering Cancer Center (MSKCC) or Motzer Score is a prognostic model used to risk-stratify patients with metastatic renal cell carcinoma (mRCC). Originally developed in the cytokine era, it remains a historical benchmark and is still used in some clinical trials and settings, though IMDC is often preferred for targeted therapy.
Primary Source EvidenceMotzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20(1):289-296.
Formula Logic
Sum of 5 risk factors (1 point each).

Reference Data

Risk GroupRisk FactorsMedian Overall Survival (Historical)
Favorable Risk030 months
Intermediate Risk1 - 214 months
Poor Risk≥ 35 months

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use MSKCC (Motzer) Score when mSKCC (Motzer) Score stratifies metastatic renal cell carcinoma into risk groups to guide first-line systemic therapy selection for mRCC patients.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Favorable Risk through Poor Risk.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm histology, localized versus metastatic setting, nephrectomy status, treatment line, and imaging before selecting surveillance or systemic-therapy pathways.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Post-nephrectomy and metastatic RCC models are not interchangeable.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients undergoing localized or metastatic renal cell carcinoma prognostic assessment

How to apply this result

For a representative case, verify Karnofsky Performance Status< 80%?, Serum LDH > 1.5 x Upper Limit of Normal?, Hemoglobin < Lower Limit of Normal?, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Kidney / Renal hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

IMDC (Heng) Risk Criteria Calculator — Metastatic Renal Cell CarcinomaLeibovich Score (RCC)SSIGN Score (Mayo)

Frequently Asked Questions

When should MSKCC (Motzer) Score be used?

Use it for patients undergoing localized or metastatic renal cell carcinoma prognostic assessment when all required inputs and the intended clinical setting are confirmed.

Can MSKCC (Motzer) Score determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.